144 related articles for article (PubMed ID: 33797827)
1. CDK4 and TERT amplification in head and neck mucosal melanoma.
Lyu J; Miao Y; Yu F; Chang C; Guo W; Zhu H
J Oral Pathol Med; 2021 Nov; 50(10):971-978. PubMed ID: 33797827
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification.
Shi C; Ju H; Zhou R; Xu S; Wu Y; Gu Z; Wang Y; Chen W; Huang X; Han Y; Sun S; Li C; Wang M; Zhou G; Zhang Z; Li J; Ren G
BMC Med; 2024 May; 22(1):215. PubMed ID: 38807144
[TBL] [Abstract][Full Text] [Related]
3. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
4. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.
Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y
J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
6. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract][Full Text] [Related]
7. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Smalley KS; Lioni M; Dalla Palma M; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Mol Cancer Ther; 2008 Sep; 7(9):2876-83. PubMed ID: 18790768
[TBL] [Abstract][Full Text] [Related]
8. Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
Shi CJ; Xu SM; Han Y; Zhou R; Zhang ZY
Melanoma Res; 2021 Dec; 31(6):495-503. PubMed ID: 34483306
[TBL] [Abstract][Full Text] [Related]
9. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
[TBL] [Abstract][Full Text] [Related]
10. Getting under the skin: The role of CDK4/6 in melanomas.
Guo L; Qi J; Wang H; Jiang X; Liu Y
Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma.
Cho WC; Li W; Gu J; Wang WL; Ning J; Sfamenos S; Gill P; Nagarajan P; Curry JL; Lazar AJ; Prieto VG; Torres-Cabala CA; Aung PP
J Cutan Pathol; 2023 Sep; 50(9):845-851. PubMed ID: 37400233
[TBL] [Abstract][Full Text] [Related]
12. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
13. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
14. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
16. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France.
Moya-Plana A; Aupérin A; Obongo R; Baglin A; Ferrand FR; Baujat B; Saroul N; Casiraghi O; Vergez S; Herman P; Janot F; Thariat J; Vérillaud B; de Gabory L;
Eur J Cancer; 2019 Dec; 123():1-10. PubMed ID: 31670075
[TBL] [Abstract][Full Text] [Related]
17. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
18. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
19. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
20. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
